Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1975 1
1979 3
1982 1
1983 2
1985 1
1986 3
1987 1
1988 1
1989 1
1990 2
1992 3
1993 1
1994 3
1997 1
1998 1
2000 1
2001 2
2004 1
2005 2
2006 2
2007 8
2008 11
2009 13
2010 11
2011 8
2012 10
2013 5
2014 4
2015 8
2016 6
2017 5
2018 7
2019 8
2020 5
2021 14
2022 12
2023 11
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Hayashi K, Furuta M, Furusawa K, Hamaguchi T, Watanabe M, Inokuchi Y, Onuma S, Hashimoto I, Suematsu H, Nagasawa S, Kanematsu K, Yamada T, Notsu A, Ogata T, Oshima T, Machida N, Furuse J, Maeda S. Hayashi K, et al. Among authors: inokuchi y. Anticancer Res. 2023 Jun;43(6):2831-2840. doi: 10.21873/anticanres.16452. Anticancer Res. 2023. PMID: 37247885
Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer.
Mimura K, Ogata T, Nguyen PHD, Roy S, Kared H, Yuan YC, Fehlings M, Yoshimoto Y, Yoshida D, Nakajima S, Sato H, Machida N, Yamada T, Watanabe Y, Tamaki T, Fujikawa H, Inokuchi Y, Hayase S, Hanayama H, Saze Z, Katoh H, Takahashi F, Oshima T, Goel A, Nardin A, Suzuki Y, Kono K. Mimura K, et al. Among authors: inokuchi y. J Immunother Cancer. 2024 Jan 30;12(1):e008385. doi: 10.1136/jitc-2023-008385. J Immunother Cancer. 2024. PMID: 38290769 Free PMC article.
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer.
Mimura K, Ogata T, Yoshimoto Y, Yoshida D, Nakajima S, Sato H, Machida N, Yamada T, Watanabe Y, Tamaki T, Fujikawa H, Inokuchi Y, Hayase S, Hanayama H, Saze Z, Katoh H, Takahashi F, Oshima T, Suzuki Y, Kono K. Mimura K, et al. Among authors: inokuchi y. Commun Med (Lond). 2023 Aug 15;3(1):111. doi: 10.1038/s43856-023-00343-4. Commun Med (Lond). 2023. PMID: 37582945 Free PMC article.
Exploration of the optimal GS-441524 trough concentration for treating COVID-19.
Nakano Y, Inokuchi Y, Hayama T, Hirai T, Nishiyama M, Sueyasu Y, Yokoo K. Nakano Y, et al. Among authors: inokuchi y. Int J Antimicrob Agents. 2023 Aug;62(2):106892. doi: 10.1016/j.ijantimicag.2023.106892. Epub 2023 Jun 18. Int J Antimicrob Agents. 2023. PMID: 37339712 Free PMC article.
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab.
Suematsu H, Kano K, Yamada T, Hashimoto I, Watanabe H, Takahashi K, Watanabe M, Hayashi K, Kaneta Y, Furuta M, Inokuchi Y, Machida N, Aoyama T, Tamagawa H, Yukawa N, Rino Y, Masuda M, Ogata T, Oshima T. Suematsu H, et al. Among authors: inokuchi y. Anticancer Res. 2022 Mar;42(3):1535-1540. doi: 10.21873/anticanres.15626. Anticancer Res. 2022. PMID: 35220249
Age-related decline in the taurine content of the skin in rodents.
Yoshimura T, Inokuchi Y, Mutou C, Sakurai T, Nagahama T, Murakami S. Yoshimura T, et al. Among authors: inokuchi y. Amino Acids. 2021 Mar;53(3):429-434. doi: 10.1007/s00726-021-02956-2. Epub 2021 Feb 20. Amino Acids. 2021. PMID: 33608821 Free PMC article.
174 results